146 related articles for article (PubMed ID: 16363556)
21. Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Ikuma M; Hishida A; Ishizaki T
Clin Pharmacol Ther; 2006 Nov; 80(5):539-48. PubMed ID: 17112810
[TBL] [Abstract][Full Text] [Related]
22. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
Padol S; Yuan Y; Thabane M; Padol IT; Hunt RH
Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.
Kawai T; Kawakami K; Mikinori K; Takei K; Itoi T; Moriyasu F; Takagi Y; Aoki T; Watanebe K; Matsumoto Y; Rimbara E; Noguchi N; Sasatsu M
Hepatogastroenterology; 2007 Mar; 54(74):649-54. PubMed ID: 17523342
[TBL] [Abstract][Full Text] [Related]
24. [Usefulness of new triple therapy containing PPI].
Tanabe H; Watari J; Shibata N; Satoh T; Yokota K; Kohgo Y
Nihon Rinsho; 2001 Feb; 59(2):314-8. PubMed ID: 11218404
[TBL] [Abstract][Full Text] [Related]
25. Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
Kita T; Sakaeda T; Aoyama N; Sakai T; Kawahara Y; Kasuga M; Okumura K
Biol Pharm Bull; 2002 Jul; 25(7):923-7. PubMed ID: 12132671
[TBL] [Abstract][Full Text] [Related]
26. [Recent topics on important drugs for H. pylori eradication: Lansoprazole].
Fukuda Y; Tomita T; Koizuka H; Aoyama N
Nihon Rinsho; 2005 Nov; 63 Suppl 11():338-49. PubMed ID: 16363557
[No Abstract] [Full Text] [Related]
27. Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.
Okudaira K; Furuta T; Shirai N; Sugimoto M; Miura S
Aliment Pharmacol Ther; 2005 Feb; 21(4):491-7. PubMed ID: 15710002
[TBL] [Abstract][Full Text] [Related]
28. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Horn J
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori.
Furuta T; Shirai N; Ohashi K; Ishizaki T
Methods Find Exp Clin Pharmacol; 2003 Mar; 25(2):131-43. PubMed ID: 12731459
[TBL] [Abstract][Full Text] [Related]
30. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori.
Schwab M; Schaeffeler E; Klotz U; Treiber G
Clin Pharmacol Ther; 2004 Sep; 76(3):201-9. PubMed ID: 15371981
[TBL] [Abstract][Full Text] [Related]
31. [Tailor-made medicine in Helicobacter pylori eradication therapy].
Aoyama N; Shirasaka D; Miki I
Nihon Rinsho; 2003 Jan; 61(1):129-36. PubMed ID: 12607330
[TBL] [Abstract][Full Text] [Related]
32. Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy.
Sugimoto M; Furuta T; Shirai N; Ikuma M; Hishida A; Ishizaki T
Clin Pharmacol Ther; 2006 Jul; 80(1):41-50. PubMed ID: 16815316
[TBL] [Abstract][Full Text] [Related]
33. CYP2C19 genotype and the PPIs--focus on rabeprazole.
Lim PW; Goh KL; Wong BC
J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346
[TBL] [Abstract][Full Text] [Related]
34. [Concomitant dosing of a H2 receptor antagonist (H2RA) with a triple therapy increases the cure rate of Helicobacter pylori infection].
Okudaira K; Miura S; Furuta T; Sugimoto M; Shirai N
Nihon Rinsho; 2005 Nov; 63 Suppl 11():391-6. PubMed ID: 16363566
[No Abstract] [Full Text] [Related]
35. Should the presence of polymorphisms of CYP2C19 enzymes influence the choice of the proton pump inhibitor for treatment of Helicobacter pylori infection?
van Zanten SV; Thompson K
Am J Gastroenterol; 2006 Jul; 101(7):1476-8. PubMed ID: 16863548
[TBL] [Abstract][Full Text] [Related]
36. [Dosaging of proton pumps inhibitors].
Brørs O
Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2397-9. PubMed ID: 16998554
[No Abstract] [Full Text] [Related]
37. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
Furuta T; Shirai N; Xiao F; Takashita M; Sugimoto M; Kajimura M; Ohashi K; Ishizaki T
Hepatogastroenterology; 2003; 50(54):2274-8. PubMed ID: 14696516
[TBL] [Abstract][Full Text] [Related]
38. Effect of omeprazole and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the healing of duodenal ulcer: comparison with a historical control.
Schütze K; Hentschel E; Hirschl AM
Hepatogastroenterology; 1999; 46(28):2358-62. PubMed ID: 10521998
[TBL] [Abstract][Full Text] [Related]
39. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
Furuta T; Sugimoto M; Shirai N; Ishizaki T
Pharmacogenomics; 2007 Sep; 8(9):1199-210. PubMed ID: 17924835
[TBL] [Abstract][Full Text] [Related]
40. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori.
Furuta T; Sugimoto M; Shirai N; Matsushita F; Nakajima H; Kumagai J; Senoo K; Kodaira C; Nishino M; Yamade M; Ikuma M; Watanabe H; Umemura K; Ishizaki T; Hishida A
Aliment Pharmacol Ther; 2007 Sep; 26(5):693-703. PubMed ID: 17697203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
